首页> 外文期刊>Drug Design, Development and Therapy >Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization
【24h】

Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization

机译:新型脱氢表雄酮辅酶可改善接受体外受精的妇女的血清雄激素水平

获取原文
           

摘要

Abstract: Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in the circulation and has potent multifunctional activity. Epidemiological evidence suggests that levels of serum DHEA decrease with advancing age, and this has been associated with onset or progression of various age-related ailments, including cognitive decline and dementia, cardiovascular disease, and obesity. Consequently, these findings have sparked intense research interest in DHEA supplementation as an “antiaging” therapy. Currently, DHEA is being used by 25% of in vitro fertilization (IVF) clinicians as an adjuvant in assisted reproductive programs, yet the therapeutic benefit of DHEA is unclear. Here, we examined the use of novel DHEA-containing oral troches in patients undertaking IVF and investigated the impact of these troches on their serum androgen profile. This retrospective study determined the androgen profile of 31 IVF patients before (baseline) and after DHEA supplementation (with DHEA). Baseline serum measurements of testosterone (total and free), DHEA sulfate (DHEAS), sex hormone-binding globulin (SHBG), and androstenedione were made before and after supplementation. Each patient received DHEA troches containing 25 mg of micronized DHEA, and troches were administered sublingually twice daily for a period of no greater than 4 months. Adjuvant treatment with DHEA boosted the serum concentration of a number of androgen-related analytes, including total and free testosterone, androstenedione, and DHEAS, while serum SHBG remained unchanged. Supplementation also significantly increased the free-androgen index in IVF patients. Interestingly, the increase in serum analyte concentration following DHEA supplementation was found to be dependent on body mass index (BMI), but not individual age. Patients with the lowest BMI (30.0 kg/m2) tended to have lower androgen responses following DHEA supplementation, but these were not statistically different from the corresponding baseline level. This method of DHEA administration results in a similar enhancement of testosterone, DHEAS, and androstenedione levels in comparison with other methods of administration. Furthermore, we showed that BMI significantly influences DHEA uptake and metabolism, and that BMI should be carefully considered during dosage calculation to ensure a significant and robust androgen-profile boost.
机译:摘要:脱氢表雄酮(DHEA)是循环中最丰富的类固醇激素,具有强大的多功能活性。流行病学证据表明,血清DHEA水平随着年龄的增长而降低,这与各种与年龄有关的疾病的发作或进展有关,包括认知能力下降和痴呆,心血管疾病和肥胖。因此,这些发现激发了人们对脱氢表雄酮补充作为“抗衰老”疗法的浓厚研究兴趣。目前,有25%的体外受精(IVF)临床医生正在使用DHEA作为辅助生殖程序的佐剂,但是DHEA的治疗益处尚不清楚。在这里,我们检查了接受试管婴儿的患者中使用新型含DHEA的口腔锭剂,并研究了这些锭剂对其血清雄激素谱的影响。这项回顾性研究确定了31名IVF患者在补充DHEA之前(基线)和之后(与DHEA)的雄激素谱。在补充之前和之后,对睾丸激素(全部和游离),硫酸脱氢表雄酮(DHEA),性激素结合球蛋白(SHBG)和雄烯二酮进行基线血清测量。每位患者均接受含有25 mg DHEA微粉的DHEA锭剂,每天两次舌下给予锭剂,疗程不超过4个月。 DHEA的辅助治疗可提高许多雄激素相关分析物的血清浓度,包括总睾丸激素和游离睾丸激素,雄烯二酮和DHEAS,而血清SHBG则保持不变。补充剂还显着增加了IVF患者的游离雄激素指数。有趣的是,发现补充DHEA后血清分析物浓度的增加取决于体重指数(BMI),而不取决于个体年龄。 BMI最低(30.0 kg / m2)的患者在补充DHEA后往往具有较低的雄激素反应,但与相应的基线水平在统计学上无差异。与其他给药方法相比,这种DHEA给药方法导致睾丸激素,DHEAS和雄烯二酮水平有类似的提高。此外,我们表明BMI显着影响DHEA的摄取和代谢,并且在剂量计算过程中应仔细考虑BMI,以确保显着而强大的雄激素分布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号